RT Journal Article
SR Electronic
T1 Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.20.21266644
DO 10.1101/2021.11.20.21266644
A1 Nasamon Wanlapakorn
A1 Ritthideach Yorsaeng
A1 Harit Phowatthanasathian
A1 Nungruthai Suntronwong
A1 Sitthichai Kanokudom
A1 Natthinee Sudhinaraset
A1 Yong Poovorawan
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.20.21266644.abstract
AB Introduction In August 2021, Thailand imported the BNT162b2 mRNA COVID-19 vaccine. The prioritised group to receive the BNT162b2 vaccine were health professionals. The BNT162b2 vaccine scheduled for healthcare workers were two-dose regimen administered three weeks apart, the third dose booster in two-dose inactivated CoronaVac vaccine recipients or as a second dose in health professionals who had received the CoronaVac or adenoviral-vectored (ChAdOx1-S) vaccine as the first dose regardless of the interval between the first and second dose.Methods This study aims to evaluate the immunogenicity of the heterologous prime boost CoronaVac followed by BNT162b2 in health professionals.Results The CoronaVac/BNT162b2 vaccine recipients elicited higher neutralizing activity against the original Wuhan and all variants of concern than in the recipients of the two-dose CoronaVac.Conclusions The heterologous CoronaVac/BNT162b2 could be used as an alternative regimen in countries experiencing the vaccine shortages and in individuals experiencing the adverse events following CoronaVac.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The National Research Council of Thailand (NRCT), Health Systems Research Institute, The Center of Excellence in Clinical Virology of Chulalongkorn University, and King Chulalongkorn Memorial Hospital.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University (IRB 870/64).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript